ArticleDiabetes & metabolic syndrome2007
Metabolic Syndrome Prevalence in an Urban African American Population.
Article in Diabetes & metabolic syndrome, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Multi-tissue metabolomics reveal mtDNA- and diet-specific metabolite profiles in a mouse model of cardiometabolic disease.Redox biology · 2025Article
- Feasibility of a behavioral automaticity intervention among African Americans at risk for metabolic syndrome.BMC public health · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe metabolic syndrome (MeS) is a clustering of a group of metabolic risk factors in one person that predisposes to higher risk of cardiovascular disease (CVD) and type II diabetes. The metabolic syndrome has become increasingly common in the United States. With the increase in CVD morbidity and mortality among US adult populations, particularly African Americans, it becomes urgent to monitor and control metabolic syndrome in an effort to inform effective CVD prevention programs. We sought to assess the prevalence of and predictors of MeS syndrome in an urban, high risk, predominantly African American hypertensive population.
methodsThe study is part of the NHLBI U01 grant "Baltimore Partnership Programs to Reduce Cardiovascular Disparities". A sample of 150 earlier enrolled patients was selected. Risk factors for metabolic syndrome were assessed at baseline, and include risk factors of abdominal obesity (BMI = 30), high triglycerides (triglycerides = 150 mg/dL), low HDL cholesterol (HDL < 40 mg/dL in men, or HDL <50 mg/dL in women), elevated blood pressure (BP = 130/85 mmHg), and elevated fasting glucose (blood glucose = 100 mg/dL) - per ATP III criteria. We assessed the prevalence of MeS in general and across subgroups, and predictors of MeS were assessed using logistic regression.
findingsThe prevalence of MeS in this group of patients was 40%. Significant predictors of MeS include presence of diabetes (P = 0.03; OR = 3.03, 95% CI: 1.07-8.54), younger than 64 (P = 0.04; OR = 2.38, 95% CI: 1.02-5.56), and female gender (P = 0.02; OR = 2.63; OR = 1.18-5.88). The effect of self-perceived health status remain marginally significant (P = 0.13).
interpretationIn this patient sample, the prevalence of MeS is higher than estimates based on the US general population. Our findings of factors associated with MeS are consistent with existing studies, with the exception of age factor, suggesting the impact of higher treatment rate and better medication compliance among elderly patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.